{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"28.1","value":"14.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Time to progression post transplant: For patients not in Complete Response (CR), progressive disease requires one or more: \\>25% increase in the level of the serum monoclonal paraprotein(absolute increase of at least 0.5 g/dL); \\> 25% increase in 24-hour urinary light chain excretion(absolute increase of at least 200m/24 hours). Increase plasma cells in a bone marrow aspirate( absolute increase of at least 10%). Definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of new bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum Ca \\> 11.5 mg/dL or \\> 2.65 mmol/L) not attributable to any other cause. All relapse categories require two consecutive assessments made any time before classification as relapse or progressive disease.","dispersionType":"Full Range","groups":[{"description":"azacitidine: 75 mg/sq m daily for 5 days\n\nlenalidomide: 10 mg p.o. daily, Days 6-21","id":"OG000","title":"5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant"}],"paramType":"MEDIAN","populationDescription":"Progression is collected anytime after transplant.","reportingStatus":"POSTED","timeFrame":"28 months","title":"Time to Progression Post Transplant","type":"SECONDARY","unitOfMeasure":"months"}